Public-private partnerships in the healthcare industry

Our client, a French medical device company, considered bringing innovative products via open innovation as one of the main pillars of its R&D strategy. To do so, our client needed to rely on partnerships with both public and private institutions.

We supported our client to identify relevant partners for open innovation. Firstly, we detected the existing best practices internally within the existing similar partnerships. Secondly, we identified top academic players (hospital research teams) with capabilities in relevant therapeutic areas and digital technologies required by the customer. Thirdly, we characterized these players according to scientific criteria and their willingness / motivation to collaborate with our customer.

To help our client select the most pertinent partners, we defined the selection criteria and ranked the players accordingly. At the end, we recommended our customer the TOP 3 players for further direct discussion.

Alcimed supported an industrial player in understanding Asian players that specialize in gene engineering-based botulinum toxin production.

With a focus on several Asian countries, our team identified and characterized the key academic and industrial players using genetic engineering to produce botulinum toxin. We then interacted directly with key stakeholders involved in this research domain and performed an in-depth desk research to gain a comprehensive understanding of the landscape for our client.

Through this project, we helped our client have an overview of current research in this field, as well as an understanding of the most relevant players in their target geography. Our client could finally identify the most relevant business opportunities and potential partnerships.

Alcimed supported a biotech company in understanding the strategic implications of bringing new therapies to market in a country that requires local manufacturing to enter the public healthcare market.

First of all, our team assessed the terms of previous public-private partnership deals as benchmarks for what could be expected at each level of development and commercialization. We analyzed historically fruitful collaborations with other companies and interviewed business development leaders. Then we structured a framework to approach the country’s government on suitable terms for both the public strucuture and the client, highlighting requirements and points of negotiation.

As a result, the client received a strategic plan on how to negotiate with the local stakeholders as well as advice on how to make a go/no go decision on future deals, based on the impact on IP protection and other strategic considerations.

Alcimed supported a pharma company to identify the most relevant public and semi-public funding opportunities to finance an R&D translational center in a specific region.

To do so, our team performed desk research to identify existing partnerships between pharma companies and public funding bodies in the region. Moreover, we mapped public funding opportunities for clinical and/or translational research. Finally, we interviewed KOLs to assess the interest of the local governments to collaborate with foreign companies and the attractiveness of the research ecosystem with a focus on specific technology areas.

Thanks to our work, our client could prioritize what country to target based on a thorough understanding of the research landscape and of the main public funding agencies sponsoring programs for translational research in each country.